iBio Selects Fusion Protein as Lead Candidate for New Scleroderma Treatment
iBio has selected a lead scleroderma treatment candidate — a molecule it calls the E4-Fc fusion protein. The company plans to continue developing it, with a goal of moving it in clinical trials in people. It also hopes to treat fibrotic diseases besides scleroderma with the molecule, which is…